The Editor,

Sir,

Following the first description of Cannabinoid Hyperemesis Syndrome (CHS) in 2004, there have been hundreds of cases reported, up to recently. One of the largest series was at the Mayo Clinic (a non-profit organization in the United States of America) where five African-American patients, three Hispanics and 12 patients of ‘Other’ ethnicities were noted in a series of 98 cases of predominantly Caucasian patients (1, 2).